UPDATE: AEterna Zentaris (AEZs) PT Raised to $4 at Maxim Group; Macrilen Could Become the New Standard

(Updated - July 19, 2017 12:54 PM EDT)

(updated to include analyst comments)

Maxim Group raised its price target on Æterna Zentaris (NASDAQ: AEZs) to $4.00 (from $2.00) while maintaining a Buy rating after FDA has set a December 30, 2017 Year End PDUFA date for Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults (“AGHD”)

Jason Kolbert notes that if approved Macrilen would be the only FDA-approved drug for the assessment of AGHD.

He highlights that the only test used for AGHD, the insulin tolerance test (ITT), is difficult to perform and has significant risks for the patient. Macrilen is a safer test than ITT and can be repeated with accuracy multiple times.

"Macrilen could become the new standard for addressing AGHD and be rapidly adopted by physicians," he adds.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Teradyne (TER) PT Raised to $125 at TD Cowen
• LTIMindtree Ltd (LTIM:IN) PT Lowered to INR5,380 at HSBC
• INmune Bio (INMB) Prices 986K Share Offering at $9.84/sh